Jazz Pharmaceuticals plc (JAZZ) SEC Filings & Earnings Calls

Leadership transition in commercial role may disrupt sales execution or strategy.

“Departure of Chief Commercial Officer; successor not yet identified.”

Integration risk and execution risk for ABS-1230 clinical development; $820M upfront cost may pressure near-term cash flows.

“Acquisition for $820M upfront; ABS-1230 is still in clinical development with regulatory and commercial uncertainties.”

Potential dilution from note exchange; debt service costs

“Up to 5M shares issuable; 1.875% coupon”

Commercial execution risk; competition from other HER2-targeted therapies.

“Approval for first-line treatment; market adoption and reimbursement uncertain.”

Acquisition subject to regulatory approvals, HSR clearance, and stockholder approval; may not close.

“Conditions include HSR Act waiting period, stockholder vote, and no Material Adverse Effect.”

Milestone payments contingent on regulatory and commercial success; may not be achieved.

“Milestones depend on regulatory approval and sales targets.”

Clinical and regulatory risk for ABS-1230; integration risk.

“ABS-1230 is in Phase 1b/2a; no approved therapies for KCNT1+ epilepsy.”

Generic Xywav Competition

“We received notices in June 2021, February 2023 and July 2025 that Lupin, Teva and Granules, respectively, filed ANDAs for generic versions of Xywav. In January 2026, we received notices from Tris Pharma that it had filed with FDA a Section 505(b)(2) NDA with Xyrem and Xywav as referenced listed drugs.” · word for word

Zepzelca Second-Line Indication Removal

“Based on the results from the LAGOON trial of Zepzelca in second-line metastatic SCLC, which were reported in June 2026, and in alignment with FDA, in the third quarter of 2026, we will submit for FDA's review and subsequent action a labeling supplement to remove the second-line indication.” · word for word

IRA Drug Pricing Impact

“The IRA, among other things, requires the HHS Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026 and penalizes manufacturers of certain Medicare Parts B and D drugs for price increases above inflation.” · word for word

High Debt and Refinancing Risk

“We have a significant amount of debt outstanding on a consolidated basis. ... As of June 30, 2026, we had cash, cash equivalents and investments of $2.2 billion, borrowing available under our Amended Revolving Credit Facility of $885.0 million and a long-term debt principal balance of $4.4 billion.” · word for word

Tariff Exposure

“The U.S. government has imposed and may seek to impose additional restrictions on international trade, such as tariffs on goods generally, and pharmaceutical and biological products in particular, imported into the U.S. ... we anticipate that our margins could be adversely affected, depending on the ultimate scope and duration of tariffs imposed.” · word for word

Dependence on key products and upcoming patent expirations

“Xywav and Epidiolex represent significant portion of revenue; Xyrem declining.”

Regulatory and clinical trial risks for pipeline assets

“Zanidatamab PDUFA date August 25, 2026; Modeyso OS interim analysis in 1H27.”

Net loss in 2025

“Net Income (Loss) ($ in thousands) 2025: (356,148)”

CEO transition risk

“Ms. Gala was appointed President, CEO and Director effective as of August 11, 2025.” · word for word

Reliance on key products

“Xywav net product sales were $1,657.0 million in 2025. Epidiolex/Epidyolex net product sales were $1,059.2 million in 2025.” · word for word

Generic competition for oxybate franchise

“In March 2026, Amneal and Ascent began dispensing their generic high-sodium oxybate products through the generic sodium oxybate REMS.” · word for word

Drug pricing regulation (IRA, MFN)

“the IRA, among other things, requires the HHS Secretary to negotiate... the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026” · word for word

Tariff exposure on imported products

“In anticipation of the potential for increased tariffs on our products, we have increased inventory levels of our products in the U.S.” · word for word

CEO transition risk

“The compensation committee believed that these grants would help minimize business risk and ensure overall organizational stability and continuity during this period of leadership transition” · word for word

TSR underperformance risk

“our TSR ranked in the 47th percentile against peers, which reduced the payout by 3%” · word for word

Oxybate franchise revenue concentration

“Our inability to maintain revenues from our oxybate franchise would have a material adverse effect on our business, financial condition, results of operations and growth prospects.” · word for word

Generic competition for Xyrem

“As of January 2026, we are aware of two high-sodium oxybate generics of Xyrem that have been launched.” · word for word

Lumryz competition for Xywav

“Lumryz, a fixed-dose, high-sodium oxybate, was approved by FDA on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy and was launched in the U.S. market in June 2023.” · word for word

Epidiolex generic entry risk

“Under the settlement agreements, we granted each of the Epidiolex ANDA Filers a license to manufacture, market, and sell its own generic version of Epidiolex beginning in the very late 2030s” · word for word

Debt service burden

“We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position” · word for word

GAAP net loss due to non-cash charges; Xywav growth may moderate.

“GAAP net loss of $356M in FY2025; Xywav guidance flat to up mid-single digits in 2026.”

Dependence on key products Xywav, Epidiolex, Modeyso for revenue

“Revenue expectations provided for Xywav, Epidiolex and Modeyso”

Patent litigation settled but future competition possible

“Settled outstanding ANDA litigation = Acquisition durability into the very-late 2030's” · word for word

Oxybate franchise revenue decline

“These AG products have negatively impacted and are expected to continue to negatively impact Xyrem and Xywav sales for patients with narcolepsy.” · word for word

Drug pricing regulation

“the Inflation Reduction Act of 2022 among other things, requires the U.S. Department of Health and Human Services Secretary to negotiate, with respect to Medicare units and subject to a specified cap, the price of a set number of certain high Medicare spend drugs and biologicals per year starting in 2026” · word for word

Generic Xywav competition

“On October 13, 2023, Lupin announced that it has received tentative approval for its application to market a generic version of Xywav.” · word for word

Clinical trial failure

“The trial did not meet the primary efficacy endpoint of a pre-specified percentage change in indication-associated seizure frequency during the treatment period (up to 16 weeks) compared to baseline in Japanese pediatric patients.” · word for word

Dependence on key products; Xyrem decline continues.

“Xyrem net product sales decreased 39% to $35.7M in 3Q25 from $58.1M in 3Q24.”

Oncology portfolio growth reliant on new launches; Zepzelca declining.

“Zepzelca net product sales decreased 8% to $79.3M in 3Q25.”

Board transition is routine and not indicative of operational issues

“Retirement not due to any dispute or disagreement”